| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 42,695 | 22,327 | ||
| Prepaid expenses and other current assets | 7,592 | 7,199 | ||
| Total current assets | 50,287 | 29,526 | ||
| Right of use asset, net | 249 | 386 | ||
| Subtotal | 138 | - | ||
| Less accumulated depreciation | 63 | - | ||
| Property and equipment, net | 75 | 83 | ||
| Total assets | 50,611 | 29,995 | ||
| Warrant liability | 9,147 | 10,214 | ||
| Accounts payable | 957 | 775 | ||
| Accrued liabilities | 2,762 | 2,168 | ||
| Operating lease liability - current | 265 | 409 | ||
| Total current liabilities | 13,131 | 13,566 | ||
| Operating lease liability long term | 0 | 0 | ||
| Total liabilities | 13,131 | 13,566 | ||
| Common stock, 0.001 par value per share 400,000,000 shares authorized at december 31, 2024, and september 30, 2025 11,384,236 and 20,850,363 shares issued and outstanding at december 31, 2024, and september 30, 2025, respectively | 21 | 122 | ||
| Additional paid-in capital | 150,617 | 123,454 | ||
| Accumulated deficit | -113,158 | -107,147 | ||
| Preferred stock, value-Series A2Preferred Stock | 0 | 0 | ||
| Preferred stock, value-Series B2Preferred Stock | 0 | 0 | ||
| Preferred stock, value | 0 | 0 | ||
| Total stockholders equity | 37,480 | 16,429 | ||
| Total liabilities and stockholders equity | 50,611 | 29,995 | ||
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)